Cautionary findings on acquired immunodeficiency from anti-CD20 MS therapyMay 1, 2020Multiple Sclerosis
FDA approves ozanimod for relapsing and secondary progressive forms of MSMarch 26, 2020Multiple Sclerosis
Teriflunomide increases the likelihood of achieving NEDA in relapsing-remitting MSMarch 12, 2020Multiple Sclerosis
Age does not appear to affect efficacy of siponimod in secondary progressive MSMarch 10, 2020Multiple Sclerosis
